3 questions with…
Director of R&D Operations
What are the biggest challenges in the advanced therapy industry?
This is difficult to answer as there are multiple challenges some of which are common to gene therapies, others common to autologous cell therapies and others common to allogeneic/PSC derived cell therapies. Manufacturing and product characterisation are key challenges that the whole field faces to varying degrees with impact on scalability and safety. We need better methods to characterise our products which will help us develop more consistent and scalable processes. This will ultimately improve safety, efficacy and patient access so everyone wins.
What advanced therapy innovations are you most excited about?
What are your predictions for the next 5 years for the Advanced Therapy Industry?